Edge Therapeutics Inc (EDGE)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Edge Therapeutics Inc (EDGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014174
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Edge Therapeutics Inc (Edge Therapeutics) is a clinical-stage biotechnology company that discovers, develops and commercializes a range of hospital-based therapies. The company offers hospital based therapies capable of transforming treatment paradigms in the management of life-threatening, acute neurological conditions. Its lead pipeline products include EG-1962, a proprietary formulation, which is used to treat aneurysmal subarachnoid hemorrhage, is in Phase 3 clinical trials and EG-1964 is in preclinical stage used to prevent recurrent chronic subdural hematoma. The company’s Precise, a proprietary, programmable, biodegradable polymer-based development platform develops products for the treatment of acute neurological conditions. Edge Therapeutics is headquartered in Berkeley Heights, New Jersey, the US.

Edge Therapeutics Inc (EDGE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Edge Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Edge Therapeutics Raises USD56 Million in Series C-2 Financing 11
Edge Therapeutics Raises USD16.5 Million in Series C-1 Financing 13
Edge Therapeutics Raises USD8 Million in Venture Financing 14
Edge Therapeutics Secures USD3 Million from Hercules Technology 15
Edge Therapeutics Raises US$18 Million In Series C Financing 16
Partnerships 17
Edge Therapeutics Enters into Agreement with Oakwood Labs 17
Edge Therapeutics Enters into Research and Discovery Agreement with St. Michael’s Hospital 18
Equity Offering 19
Edge Therapeutics Raises USD18 Million in Private Placement of Shares 19
Edge Therapeutics Raises USD92.5 Million in IPO 21
Edge Therapeutics Raises USD0.15 Million in Private Placement of Preferred Stock 23
Edge Therapeutics Raises USD2.6 Million in Private Placement of Preferred Stock 24
Edge Therapeutics Raises USD3.4 Million in Private Placement of Preferred Stock 25
Edge Therapeutics Raises USD2.5 Million in Private Placement of Preferred Stock 26
Edge Therapeutics Raises USD0.6 Million in Private Placement of Preferred Stock 27
Debt Offering 28
Edge Therapeutics Raises USD0.1 Million in Private Placement of Notes 28
Edge Therapeutics Raises USD0.15 Million in Private Placement of Notes 29
Edge Therapeutics Inc – Key Competitors 30
Edge Therapeutics Inc – Key Employees 31
Edge Therapeutics Inc – Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Financial Announcements 33
Nov 01, 2017: Edge Therapeutics Reports Third Quarter 2017 Financial Results 33
Aug 01, 2017: Edge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational Progress 35
May 03, 2017: Edge Therapeutics Q1 net loss increases 36
May 03, 2017: Edge Therapeutics Reports First Quarter 2017 Financial Results and Continued Operational Progress 37
Mar 02, 2017: Edge Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results 38
Nov 01, 2016: Edge Therapeutics Reports Third Quarter Financial Results 39
Aug 03, 2016: Edge Therapeutics Reports Second Quarter Financial Results and Recent Highlights 40
May 03, 2016: Edge Therapeutics Reports First Quarter 2016 Financial Results 41
Mar 08, 2016: Edge Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results 42
Corporate Communications 44
Sep 19, 2017: Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of Directors 44
Feb 21, 2017: Edge Therapeutics appoints senior vice president of regulatory affairs 45
Oct 17, 2016: Edge Therapeutics Appoints Chief Operating Officer 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Edge Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Edge Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Edge Therapeutics Raises USD56 Million in Series C-2 Financing 11
Edge Therapeutics Raises USD16.5 Million in Series C-1 Financing 13
Edge Therapeutics Raises USD8 Million in Venture Financing 14
Edge Therapeutics Secures USD3 Million from Hercules Technology 15
Edge Therapeutics Raises US$18 Million In Series C Financing 16
Edge Therapeutics Enters into Agreement with Oakwood Labs 17
Edge Therapeutics Enters into Research and Discovery Agreement with St. Michael’s Hospital 18
Edge Therapeutics Raises USD18 Million in Private Placement of Shares 19
Edge Therapeutics Raises USD92.5 Million in IPO 21
Edge Therapeutics Raises USD0.15 Million in Private Placement of Preferred Stock 23
Edge Therapeutics Raises USD2.6 Million in Private Placement of Preferred Stock 24
Edge Therapeutics Raises USD3.4 Million in Private Placement of Preferred Stock 25
Edge Therapeutics Raises USD2.5 Million in Private Placement of Preferred Stock 26
Edge Therapeutics Raises USD0.6 Million in Private Placement of Preferred Stock 27
Edge Therapeutics Raises USD0.1 Million in Private Placement of Notes 28
Edge Therapeutics Raises USD0.15 Million in Private Placement of Notes 29
Edge Therapeutics Inc, Key Competitors 30
Edge Therapeutics Inc, Key Employees 31

★海外企業調査レポート[Edge Therapeutics Inc (EDGE)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ionis Pharmaceuticals, Inc.:企業の戦略・SWOT・財務情報
    Ionis Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ionis Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Fraser & Neave Holdings Bhd:企業の戦略・SWOT・財務情報
    Fraser & Neave Holdings Bhd - Strategy, SWOT and Corporate Finance Report Summary Fraser & Neave Holdings Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Korea Electric Power Corporation (015760):企業の財務・戦略的SWOT分析
    Korea Electric Power Corporation (015760) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • SRI International:企業のM&A・事業提携・投資動向
    SRI International - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SRI International Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Columbia University-製薬・医療分野:企業M&A・提携分析
    Summary Columbia University (CU) is an educational service provider that offers educational and research programs. The university provides educational services and courses through its schools, departments, faculties, centers and institutes. It provides undergraduate and graduate courses in various d …
  • TDC AS (TDC):企業の財務・戦略的SWOT分析
    TDC AS (TDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Continental Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Continental Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Continental Resources Inc (Continental Resources) is an oil and gas company involved in the distribution of fuel and related products and services. The company offerings include supply fulf …
  • John Keells Holdings PLC (JKH.N0000):企業の財務・戦略的SWOT分析
    Summary John Keells Holdings PLC (John Keells) is a business and consumer services company that provides hotel management services. The company offers services such as airline and aviation services, cinnamon hotels and resorts services, holiday and tour consulting services, port and marine fuel serv …
  • Bio Blast Pharma Ltd (ORPN):製薬・医療:M&Aディール及び事業提携情報
    Summary Bio Blast Pharma Ltd (Bioblast Pharma) is a clinical stage biotechnology company that discovers, delivers, and develops clinical therapies for patients with rare and ultra-rare genetic diseases. The company discovers and develops pipeline products using platforms such as cabaletta, a mutant …
  • Expro Holdings UK 2 Limited:企業の戦略的SWOT分析
    Expro Holdings UK 2 Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Cohu, Inc. (COHU):企業の財務・戦略的SWOT分析
    Cohu, Inc. (COHU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Central Electricity Generating Co:発電所・企業SWOT分析
    Central Electricity Generating Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • LGC Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary LGC Ltd (LGC), formerly LGC (Teddington) Ltd is a life sciences measurement and testing company that offers reference materials, genomics solutions and analytical testing products and services. The company’s products comprise DNA extraction instrumentation, DNA extraction kits, Douglas scien …
  • PledPharma AB (PLED):企業の財務・戦略的SWOT分析
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. Its PledOX drug is used to prevent chemotherapy-induced side effects for colore …
  • Antong Holdings Co., Ltd. (600179):企業の財務・戦略的SWOT分析
    Antong Holdings Co., Ltd. (600179) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Laboratory Corp of America Holdings (LH)-医療機器分野:企業M&A・提携分析
    Summary Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of diagnostic technologies and testing services. The company offers clinical diagnostics la …
  • Envision Healthcare Corp:企業のM&A・事業提携・投資動向
    Envision Healthcare Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Envision Healthcare Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Karelia Tobacco Company Inc SA:企業の戦略・SWOT・財務情報
    Karelia Tobacco Company Inc SA - Strategy, SWOT and Corporate Finance Report Summary Karelia Tobacco Company Inc SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Academic Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary Academic Medical Center (AMC), a subsidiary of University of Amsterdam is a medical center that offers research and educational services. The center offers services such as treatment of patients, medical research and medical education. It provides medical treatments and services for various …
  • IBEX Technologies Inc (IBT):企業の財務・戦略的SWOT分析
    Summary IBEX Technologies Inc (IBEX) is a manufacturer and marketer of high-purity proprietary enzymes and recombinant from flavobacterium heparinum. The company provides enzymes such as heparinase I, heparinase II, heparinase III, chondroitinase AC and chondroitinase B. Its assays allow for the stu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆